10月9日，三生国健跌5.16%，截至发稿，报53.89元/股，成交2.27亿元，换手率0.66%，总市值332.39亿 元。 截至发稿，楼慧源累计任职时间7年30天，现任基金资产总规模40.4亿元，任职期间最佳基金回报 167.44%， 任职期间最差基金回报-15.88%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 数据显示，交银施罗德基金旗下1只基金重仓三生国健。交银医药创新股票A（004075）二季度减持 78.61万股，持有股数158.43万股，占基金净值比例为3.31%，位居第十大重仓股。根据测算，今日浮亏 损失约464.2万元。 交银医药创新股票A（004075）成立日期2017年3月23日，最新规模25亿。今年以来收益42.95%，同类 排名1149/4221；近一年收益30.68%，同类排名1720/3848；成立以来收益206.28%。 交银医药创新股票A（004075）基金经理为楼慧源。 资料显示，三生国健药业(上海)股份有限 ...

本次分红对象为权益登记日登记在册的本基金的份额持有人，权益登记日为9月24日，现金红利发放日 为9月26日。选择红利再投资方式的基金份额持有人，其红利将按2025年9月24日除息后的基金份额净值 转换为基金份额，再投资所得的基金份额自2025年9月26日可以查询、赎回。根据财政部、国家税务总 局的相关规定，基金向基金份额持有人分配的基金收益，暂免征收所得税。本基金本次分红免收分红手 续费。投资人选择红利再投资，红利再投资的份额免收申购费用。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 | 分级基金筒称 代码 | 重准日基金净值 | | 分红方案 | | | --- | --- | --- | --- | --- | | | (元) | | (元/10份) | | | 交银医药创新股票A 004075 | | 2.85 | | 1.14 | | 交银医药创新股票C 014046 | | 2.93 | | | 证券之星消息，9月23日发布《交银施罗德基金管理有限公司关于交银施罗德医药创新股票型证券投资 基金分红公告》。本次分红为20 ...

交银医药创新股票A（004075）成立日期2017年3月23日，最新规模25亿。今年以来收益40.18%，同类 排名359/4222；近一年收益46.72%，同类排名1679/3795；成立以来收益200.36%。 交银医药创新股票A（004075）基金经理为楼慧源。 截至发稿，楼慧源累计任职时间6年361天，现任基金资产总规模40.4亿元，任职期间最佳基金回报 160.35%， 任职期间最差基金回报-21.93%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 9月5日，三生国健涨5.25%，截至发稿，报57.99元/股，成交4.44亿元，换手率1.30%，总市值357.67亿 元。 资料显示，三生国健药业(上海)股份有限公司位于中国(上海)自由贸易试验区李冰路399号，成立日期 2002年1月25日，上市日期2020年7月22日，公司主营业务涉及抗体药物的研发、生产及销售业务。主营 业务收入构成为：销售商品75.24%，提供委托加工服务15.37 ...

Core Viewpoint - The article emphasizes that the current valuation of the China Medical Index (中证医疗) is at historically low levels, making it an opportune time for regular investment by ordinary investors [1]. Group 1: Market Analysis - The China Medical Index has experienced a significant adjustment period, with a peak in June 2015 and a low point at the end of 2018, followed by a recovery until the end of 2021, and has now been in a correction phase for approximately two years [5]. - The current adjustment has reached about 60% of its potential, indicating that the market may be nearing a bottom, although the duration of the adjustment is uncertain [5]. - A longer adjustment period is seen as beneficial for regular investors, as it allows for the accumulation of shares at lower prices, potentially leading to greater future gains [5]. Group 2: Investment Strategy - Ordinary investors are advised to focus on the Price-to-Book (PB) ratio for the China Medical Index, with a recommendation to start regular investments when the PB is below 20% [9]. - For more aggressive investors, a threshold of 25% to 30% is suggested for initiating investments [9]. - The article lists several actively managed medical-related funds that have been established for over six years and have a scale of over 500 million, highlighting their respective returns, with the top performer achieving a return of 178.62% since May 2017 [11]. Group 3: Fund Selection - The article provides a table of selected funds, showing their total returns and annualized returns over a period of approximately 6.2 years, with the best-performing fund yielding an annualized return of 18.00% [11]. - It emphasizes that despite current low valuations, all listed funds have positive long-term returns, suggesting that the issue lies more with the timing of investments rather than the funds themselves [12]. - The article advises investors to consider funds that have survived through market cycles and have demonstrated resilience [12].